On this episode of Investor Connect, Hall T. Martin welcomes Ronan O’Hagan, President & CEO of Bectas Therapeutics Inc., a groundbreaking biotech company focused on revolutionizing precision oncology. Based in [City, State/Country], Bectas Therapeutics is committed to developing cancer therapies that target over 400,000 patients annually who do not benefit from the existing standard-of-care treatments.

Ronan O’Hagan boasts over two decades of experience in building biotech teams and businesses, contributing to the development of more than 20 Investigational New Drugs (INDs) and four approved drugs. As the President & CEO of Bectas Therapeutics, O’Hagan leads a team with a mission to provide personalized cancer therapies, increasing the probability of success by fivefold and significantly reducing both cost and time in clinical development. The Bectas advisory board includes luminaries such as Dr. James Allison, a Nobel Laureate for his work in immune oncology, and Dr. Keith Flaherty, a serial entrepreneur in precision oncology.

Bectas Therapeutics Inc. focuses on developing cancer therapies tailored for patients who do not benefit from existing standard treatments, a population exceeding 400,000 individuals annually. Their precision approach ensures each patient receives the right drug for their specific cancer, significantly improving the chances of success and reducing costs and time in clinical development.

Ronan discusses the company’s precision cancer therapies, leveraging human patient data. Bectas aims to bring Best-In-Class therapies with a unique blood-based biomarker, promising rapid value creation and potential early exits for investors. O’Hagan emphasizes the significance of clinical proof of concept and highlights the company’s mission-driven approach to cancer health equity.

Connect with Ronan O’Hagan and Bectas Therapeutics: LinkedIn: Ronan O’Hagan; Twitter: @ohaganr

For a full transcript, click here. 

 

---

For more episodes from Investor Connect, please visit the site at: http://investorconnect.org  

Check out our other podcasts here: https://investorconnect.org/ 
For Investors check out: https://tencapital.group/investor-landing/ 
For Startups check out: https://tencapital.group/company-landing/ 
For eGuides check out: https:/_/tencapital.group/education/ 
For upcoming Events, check out https://tencapital.group/events/  

For Feedback please contact info@tencapital.group   

Please follow, share, and leave a review.

Music courtesy of Bensound.

Copyright (c) 2024, Hall Martin and investorconnect.org. All rights reserved.

Disclaimer:
Hall T Martin is the director of Investor Connect, which is a 501(c)(3) nonprofit dedicated to the education of investors for early-stage funding. All opinions expressed by Hall and podcast guests are solely their own opinions and do not reflect the opinion of Investor Connect. This podcast is for informational purposes only and should not be relied upon for the basis of investment decisions.